Resmetirom: A Breakthrough in the Treatment of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)

ABSTRACT Background and Aims Metabolic dysfunction–associated steatotic liver disease (MASLD), previously referred to as non‐alcoholic fatty liver disease (NAFLD), has become the most prevalent chronic liver disease worldwide. Its increasing incidence is closely linked with rising rates of obesity,...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Laiba Shakeel, Ayesha Shaukat, Aymar Akilimali
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Wiley 2025-06-01
Cyfres:	Health Science Reports
Pynciau:	cardiometabolic risk factors Diabetes Mellitus Type 2 elasticity imaging techniques MASLD metabolic syndrome non‐alcoholic fatty liver disease
Mynediad Ar-lein:	https://doi.org/10.1002/hsr2.70920
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!